loading
前日終値:
$117.67
開ける:
$119.03
24時間の取引高:
779.35K
Relative Volume:
0.92
時価総額:
$10.15B
収益:
$51.48M
当期純損益:
$-315.00M
株価収益率:
-34.18
EPS:
-3.5708
ネットキャッシュフロー:
$-244.00M
1週間 パフォーマンス:
+7.87%
1か月 パフォーマンス:
+1.89%
6か月 パフォーマンス:
+56.67%
1年 パフォーマンス:
+139.29%
1日の値動き範囲:
Value
$117.88
$122.37
1週間の範囲:
Value
$112.88
$122.37
52週間の値動き範囲:
Value
$50.35
$130.05

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
名前
Kymera Therapeutics Inc
Name
セクター
Healthcare (1068)
Name
電話
857-285-5314
Name
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
職員
253
Name
Twitter
Name
次回の収益日
2026-11-03
Name
最新のSEC提出書
Name
KYMR's Discussions on Twitter

Compare KYMR vs VRTX, REGN, MRNA, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
KYMR icon
KYMR
Kymera Therapeutics Inc
122.06 9.56B 51.48M -315.00M -244.00M -3.5708
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
514.99 130.64B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
803.90 80.46B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
182.56 57.48B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
963.79 61.58B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
368.08 39.20B 5.76B 514.49M 1.10B 4.4813

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-05-06 開始されました Canaccord Genuity Buy
2026-03-16 再開されました Jefferies Buy
2026-01-28 再開されました Barclays Overweight
2026-01-06 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-03 再開されました Guggenheim Buy
2025-10-24 繰り返されました B. Riley Securities Buy
2025-10-21 開始されました Mizuho Outperform
2025-09-18 繰り返されました H.C. Wainwright Buy
2025-09-17 開始されました Barclays Overweight
2025-09-16 開始されました RBC Capital Mkts Outperform
2025-07-30 再開されました B. Riley Securities Buy
2025-07-03 再開されました Morgan Stanley Overweight
2025-06-03 アップグレード B. Riley Securities Neutral → Buy
2025-06-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-06-02 アップグレード BofA Securities Neutral → Buy
2025-05-20 再開されました Stifel Buy
2025-03-13 開始されました Citigroup Buy
2024-12-10 開始されました BTIG Research Buy
2024-12-06 開始されました BMO Capital Markets Market Perform
2024-12-02 アップグレード Wells Fargo Equal Weight → Overweight
2024-11-18 開始されました Stephens Overweight
2024-09-09 再開されました Leerink Partners Outperform
2024-08-26 アップグレード Wolfe Research Peer Perform → Outperform
2024-04-22 開始されました Oppenheimer Outperform
2024-02-15 開始されました Wolfe Research Peer Perform
2024-01-04 アップグレード JP Morgan Neutral → Overweight
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-12-19 ダウングレード Wells Fargo Overweight → Equal Weight
2023-06-30 開始されました Truist Buy
2023-05-05 アップグレード Raymond James Mkt Perform → Outperform
2022-12-06 ダウングレード Credit Suisse Outperform → Neutral
2022-11-08 開始されました Raymond James Mkt Perform
2022-08-15 開始されました Jefferies Buy
2022-08-03 開始されました Goldman Buy
2022-07-20 開始されました SVB Leerink Mkt Perform
2022-04-28 開始されました Credit Suisse Outperform
2022-03-10 開始されました JP Morgan Neutral
2022-02-10 開始されました Wells Fargo Overweight
2021-09-30 開始されました B. Riley Securities Neutral
2021-09-30 開始されました Stifel Buy
2021-09-10 ダウングレード BofA Securities Buy → Neutral
2021-05-21 開始されました UBS Buy
2021-04-14 開始されました Berenberg Buy
2020-12-04 開始されました H.C. Wainwright Buy
2020-09-15 開始されました BofA Securities Neutral
2020-09-15 開始されました Cowen Outperform
2020-09-15 開始されました Guggenheim Buy
2020-09-15 開始されました Morgan Stanley Equal-Weight
すべてを表示

Kymera Therapeutics Inc (KYMR) 最新ニュース

pulisher
Sep 11, 2026

Understanding Momentum Shifts in (KYMR) - Stock Traders Daily

Sep 11, 2026
pulisher
Sep 10, 2026

Kymera Therapeutics at citigroup summit: oral immunology push gains pace By Investing.com - Investing.com Canada

Sep 10, 2026
pulisher
Sep 10, 2026

KYMR Upgraded by Wolfe Research -- Rating Raised to Outperform - GuruFocus

Sep 10, 2026
pulisher
Sep 10, 2026

Squarepoint Ops LLC Raises Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Sep 10, 2026
pulisher
Sep 09, 2026

Kymera Therapeutics at Wells Fargo conference: oral pipeline gains pace By Investing.com - Investing.com South Africa

Sep 09, 2026
pulisher
Sep 08, 2026

Fund giant T. Rowe Price holds a double-digit stake in Kymera (KYMR) - Stock Titan

Sep 08, 2026
pulisher
Sep 06, 2026

Have Kymera Therapeutics Insiders Been Selling Stock? - simplywall.st

Sep 06, 2026
pulisher
Sep 05, 2026

KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline - Stocktwits

Sep 05, 2026
pulisher
Sep 05, 2026

36,237 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Legal & General Group Plc - MarketBeat

Sep 05, 2026
pulisher
Sep 04, 2026

Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com Nigeria

Sep 04, 2026
pulisher
Sep 04, 2026

Kymera Therapeutics (NASDAQ:KYMR) Insider Brian Adams Sells 6,371 Shares of Stock - MarketBeat

Sep 04, 2026
pulisher
Sep 04, 2026

Kymera (NASDAQ: KYMR) insider plans stock sale to cover taxes - Stock Titan

Sep 04, 2026
pulisher
Sep 04, 2026

Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Sep 04, 2026
pulisher
Sep 04, 2026

Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Sep 04, 2026
pulisher
Sep 03, 2026

Can KT-621 Mark a Turning Point for Kymera Therapeutics? - The Globe and Mail

Sep 03, 2026
pulisher
Sep 03, 2026

Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - theglobeandmail.com

Sep 03, 2026
pulisher
Sep 03, 2026

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Sep 03, 2026
pulisher
Sep 03, 2026

Braidwell LP Buys 40,604 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat

Sep 03, 2026
pulisher
Sep 03, 2026

21,058 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Jupiter Topco LLC - MarketBeat

Sep 03, 2026
pulisher
Sep 03, 2026

Kymera Therapeutics to Participate in Upcoming September Investor Conferences - manilatimes.net

Sep 03, 2026
pulisher
Sep 02, 2026

Executive at Kymera Therapeutics (NASDAQ: KYMR) plans another stock sale after June trade of $4.4M - Stock Titan

Sep 02, 2026
pulisher
Sep 02, 2026

Five September events will webcast Kymera live - Stock Titan

Sep 02, 2026
pulisher
Sep 02, 2026

Man Group plc Makes New $2.19 Million Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Sep 02, 2026
pulisher
Sep 01, 2026

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses - investingnews.com

Sep 01, 2026
pulisher
Sep 01, 2026

A clinical trial testing an oral medicine for eczema has finished enrolling patients. Kymera expects topline data by year-end 2026. - Stock Titan

Sep 01, 2026
pulisher
Aug 31, 2026

Kymera Therapeutics (NASDAQ:KYMR) Gains on Higher Price Target - Kalkine Media

Aug 31, 2026
pulisher
Aug 31, 2026

KYMR Maintains Buy Rating by Guggenheim -- Price Target Raised t - GuruFocus

Aug 31, 2026
pulisher
Aug 31, 2026

Kymera Therapeutics (NASDAQ:KYMR) Given New $170.00 Price Target at Guggenheim - MarketBeat

Aug 31, 2026
pulisher
Aug 31, 2026

Guggenheim raises Kymera Therapeutics price target to $170 on STAT6 program - Investing.com Nigeria

Aug 31, 2026
pulisher
Aug 31, 2026

Yiheng Capital Management L.P. Sells 10,000 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat

Aug 31, 2026
pulisher
Aug 31, 2026

215,588 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Bank of New York Mellon Corp - MarketBeat

Aug 31, 2026
pulisher
Aug 31, 2026

Kymera Therapeutics, Inc. $KYMR Shares Sold by Alyeska Investment Group L.P. - MarketBeat

Aug 31, 2026
pulisher
Aug 30, 2026

Wellington Management Group LLP Trims Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Aug 30, 2026
pulisher
Aug 29, 2026

119,503 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by The Manufacturers Life Insurance Company - MarketBeat

Aug 29, 2026
pulisher
Aug 29, 2026

Freestone Grove Partners LP Purchases New Shares in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Aug 29, 2026
pulisher
Aug 28, 2026

20,000 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Bamco Inc. NY - MarketBeat

Aug 28, 2026
pulisher
Aug 27, 2026

Kymera Therapeutics Inc. (KYMR) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com

Aug 27, 2026
pulisher
Aug 27, 2026

Wells Fargo Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $151 - Moomoo

Aug 27, 2026
pulisher
Aug 27, 2026

Boone Capital Management LLC Purchases Shares of 113,173 Kymera Therapeutics, Inc. $KYMR - MarketBeat

Aug 27, 2026
pulisher
Aug 26, 2026

Connor Clark & Lunn Investment Management Ltd. Buys Shares of 149,908 Kymera Therapeutics, Inc. $KYMR - MarketBeat

Aug 26, 2026
pulisher
Aug 26, 2026

Kymera Therapeutics, Inc. $KYMR Stock Holdings Increased by Odyssean LLC - MarketBeat

Aug 26, 2026
pulisher
Aug 25, 2026

Nicholas Investment Partners LP Invests $6.26 Million in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Aug 25, 2026
pulisher
Aug 24, 2026

5,538,210 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by BlackRock Inc. - MarketBeat

Aug 24, 2026
pulisher
Aug 23, 2026

Deutsche Bank AG Makes New $12.16 Million Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Aug 23, 2026
pulisher
Aug 21, 2026

Piper Sandler Keeps Their Buy Rating on Kymera Therapeutics (KYMR) - The Globe and Mail

Aug 21, 2026
pulisher
Aug 21, 2026

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Aug 21, 2026
pulisher
Aug 20, 2026

Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140 - Moomoo

Aug 20, 2026
pulisher
Aug 20, 2026

B of A, Truist raise Kymera Therapeutics price targets - scanx.trade

Aug 20, 2026
pulisher
Aug 20, 2026

Eagle Health Investments LP Buys Shares of 166,148 Kymera Therapeutics, Inc. $KYMR - MarketBeat

Aug 20, 2026
pulisher
Aug 18, 2026

Merck & Co. Inc. Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Aug 18, 2026
pulisher
Aug 18, 2026

TimesSquare Capital Management LLC Purchases Shares of 157,327 Kymera Therapeutics, Inc. $KYMR - MarketBeat

Aug 18, 2026

Kymera Therapeutics Inc (KYMR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$58.52
price up icon 0.14%
$120.82
price down icon 0.15%
$38.22
price down icon 1.97%
$251.65
price up icon 3.00%
$192.86
price up icon 0.05%
ONC ONC
$368.08
price up icon 0.66%
大文字化:     |  ボリューム (24 時間):